32 Biosciences, also known as Three Squared, has secured $40.0 million in new funding from investors. This significant capital infusion is set to accelerate the company's mission to address critical unmet medical needs in gastrointestinal (GI) diseases, with an initial focus on conditions affecting the colon. The investment underscores confidence in 32 Bio's innovative approach to GI health.
The company specializes in developing a first-in-class therapeutic and discovery platform aimed at preventing and treating GI disorders. 32 Bio's work is centered on the understanding that a compromised gastrointestinal mucosal barrier is a key factor linked to increased infection risk, chronic disease development, and microbiome imbalance. The conditions targeted by their pipeline represent over $100 billion in US health system costs annually and are associated with very high patient unmet needs.
To combat these challenges, 32 Biosciences is dedicated to restoring and protecting the GI mucosal-immune system. Concurrently, the company is building a proprietary metabolomic data platform to enhance its discovery capabilities. This newly raised capital will be strategically deployed to advance 32 Bio's therapeutic pipeline, further develop its innovative platform, and expand its research and development initiatives.
The funding round positions 32 Biosciences for substantial growth as it progresses its solutions towards clinical application. The company plans to leverage this investment to drive innovation, broaden its scientific understanding of GI diseases, and ultimately bring novel treatments to patients suffering from these debilitating conditions.
.png&w=3840&q=75)
